Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma

摘要: Chimeric antigen receptor (CAR)-engineered T cells have displayed outstanding performance in the treatment of patients with hematological malignancies. However, their efficacy against solid tumors has been largely limited. In this study, human osteosarcoma cell lines were prepared, flow cytometry using antibodies CD166 was performed on different samples. CD166-specific obtained by viral gene transfer corresponding DNA plasmids and selectively expanded IL-2 IL-15. The ability CD166.BBζ CAR-T to kill CD166+ evaluated vitro vivo. expressed four lines, indicating its role as novel target for therapy. killed vitro; cytotoxicity correlated level expression tumor cells. Intravenous injection into mice resulted regression no obvious toxicity. Together, data suggest that may serve a new therapeutic strategy future clinical practice osteosarcoma.